12 Nuju 3 dinten, studi "The Lancet" diterbitkeun online, kanggo CD30 -periferal luar positip T - penderita limfoma sél, rituximab ieu, siklofosfamid, doxorubicin sareng prednisone ( A + CHP ) Langkung saé tibatan siklofosfamid, doxorubicin, vincristine sareng prednisone ( Rendang ).
Steven Horwitz, MD, ti Peringatan Sloan Kettering Kangker Center di New York City sareng kolega dilakukeun a buta ganda, placebo-dikawasa, aktip-kontrol fase 3 ulikan ngalibetkeun 452 penderita ti 132 lokasi di 17 nagara. Pasén ieu CD30-positip lymphoma sél T periferal tanpa perlakuan saméméh. Pasén kalayan rasio alokasi acak 1: 1, nampi A + CHP atanapi CHOP, sustained 6, atanapi. 8 th 21 nyaéta siklus poé.
Panaliti mendakan yén median survival-free progression (PFS) tina grup A + CHP sareng grup CHOP masing-masing 48.2 sareng 20.8 bulan. Kajadian efek samping sami diantara dua kelompok, kalebet neutropenia febril (masing-masing 18% sareng 15%) sareng neuropati periferal (52% sareng 55%, masing-masing). Kajadian ngarugikeun fatal lumangsung dina 3% sareng 4% pasien, masing-masing.
In the CHP to add this cetuximab can improve progression-free and overall survival without increasing toxicity, the study supports the A + CHP for many CD30 positive outer peripheral T new standard treatment for lymphoma pasien.
